"one-size-fits-all"? optimizing treatment duration for bacterial infections

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Geli, Patricia ^a   Laxminarayan, Ramanan ^a,b   Dunne, Michael ^c   Smith, David L ^a,d  

^a Center for Disease Dynamics Economics and Policy   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c Durata Therapeutics Inc   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COMMENSALISM; CONTROLLED STUDY; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; MATHEMATICAL MODEL; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; THEORETICAL STUDY; TREATMENT DURATION; ANIMAL; BACTERIAL COUNT; BACTERIUM; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; MICROBIOLOGY; TIME; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DRUG RESISTANCE, BACTERIAL; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855715653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029838     Document Type: Article

References (48)

1. Cohen ML, (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257: 1050-1055.
2. Guillemot D, (1999) Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol 2: 494-498.
3. Nordberg P, Monnet DL, Cars O, (2005) Antibacterial Drug Resistance. Background document for the WHO project: Priority Medicines for Europe and the World.
4. Bonhoeffer S, Lipsitch M, Levin BR, (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 94: 12106-12111.
5. Boni MF, Smith DL, Laxminarayan R, (2008) Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A 105: 14216-14221.
6. Bergstrom CT, Lo M, Lipsitch M, (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 101: 13285-13290.
7. Olofsson SK, Cars O, (2007) Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 45 (Suppl 2): S129-136.
8. Allen LV, Popovich NG, Ansel HC, (2009) Ansel's pharmaceutical dosage forms and drug delivery systems Philadelphia Wolters Kluwer Lippincott Williams & Wilkins Health.
9. Iravani A, Tice AD, McCarty J, Sikes DH, Nolen T, et al. (1995) Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch Intern Med 155: 485-494.
10. Charlton CA, Crowther A, Davies JG, Dynes J, Haward MW, et al. (1976) Three-day and ten-day chemotherapy for urinary tract infections in general practice. Br Med J 1: 124-126.
11. de Bock GH, Dekker FW, Stolk J, Springer MP, Kievit J, et al. (1997) Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. J Clin Epidemiol 50: 881-890.
12. de Saintonge DMC, Levine DF, Savage IT, Burgess GW, Sharp J, et al. (1982) Trial of three-day and ten-day courses of amoxycillin in otitis media. Br Med J (Clin Res Ed) 284: 1078-1081.
13. Norrby SR, (1990) Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 12: 458-467.
14. Saginur R, Nicolle LE, (1992) Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group. Arch Intern Med 152: 1233-1237.
15. Stalman W, van Essen GA, van der Graaf Y, de Melker RA, (1997) The end of antibiotic treatment in adults with acute sinusitis-like complaints in general practice? A placebo-controlled double-blind randomized doxycycline trial. Br J Gen Pract 47: 794-799.
16. Williams JW, Holleman DR, Samsa GP, Simel DL, (1995) Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA 273: 1015-1021.
17. Austin DJ, Anderson RM, (1999) Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci 354: 721-738.
18. Austin DJ, White NJ, Anderson RM, (1998) The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 194: 313-339.
19. Hyatt JM, Nix DE, Stratton CW, Schentag JJ, (1995) In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1711-1716.
20. Nolting A, Dalla Costa T, Rand KH, Derendorf H, (1996) Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13: 91-96.
21. Mouton JW, Vinks AA, Punt NC, (1997) Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41: 733-738.
22. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, et al. (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45: 845-851.
23. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48: 3670-3676.
24. Casadevall A, Pirofski LA, (2000) Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 68: 6511-6518.
25. Pezesk pour FZ, Miri S, Ghasemi R, Farid R, Ghenaat J, (2007) Skin Colonization With Staphylococcus Aureus In Patients With Atopic Dermatitis. The Internet Journal of Dermatology 5 (1).
26. Geli P, Olofsson SK, Andersson DI, Cars O, (2005) Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 49: 5081-5091.
27. Negri MC, Lipsitch M, Blázquez J, Levin BR, Baquero F, (2000) Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 44: 2485-2491.
28. Gustafsson I, Sjolund M, Torell E, Johannesson M, Engstrand L, et al. (2003) Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother 52: 645-650.
29. Maisnier-Patin S, Andersson DI, (2004) Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 155: 360-369.
30. Froom J, Culpepper L, Grob P, Bartelds A, Bowers P, et al. (1990) Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. BMJ 300: 582-586.
31. Froom J, Culpepper L, Jacobs M, DeMelker RA, Green LA, et al. (1997) Antimicrobials for acute otitis media? A review from the International Primary Care Network. BMJ 315: 98-102.
32. van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, Peeters MF, (1997) Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 349: 683-687.
33. Bezakova N, Damoiseaux RA, Hoes AW, Schilder AG, Rovers MM, (2009) Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants. BMJ 338: b2525.
34. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ, (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28: 143-160.
35. Craig WA, (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10; quiz 11-12.
36. McCaig LF, Besser RE, Hughes JM, (2002) Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287: 3096-3102.
37. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media (2004) Diagnosis and management of acute otitis media. Pediatrics 113: 1451-1465.
38. Cincinnati Children's Hospital Medical Center (2006) Evidence-based care guideline for management of acute bacterial sinusitis in children 1 to 18 years of age Jul Cincinnati (OH) Cincinnati Children's Hospital Medical Center: 1-17.
39. Department of Health: Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance (1997) The path of least resistance United Kingdom Department of Health.
40. Drusano GL, (2005) Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25: 150S-158S.
41. Rice LB, (2001) Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 7: 183-187.
42. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, et al. (1983) Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 8: 41-45.
43. Huycke MM, Sahm DF, Gilmore MS, (1998) Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 4: 239-249.
44. Handel A, Margolis E, Levin BR, (2009) Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 256: 655-662.
45. Craig JE, Nobbs A, High NJ, (2002) The extracytoplasmic sigma factor, final sigma(E), is required for intracellular survival of nontypeable Haemophilus influenzae in J774 macrophages. Infect Immun 70: 708-715.
46. Forsgren J, Samuelson A, Ahlin A, Jonasson J, Rynnel-Dagöö B, et al. (1994) Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun 62: 673-679.
47. Petersen I, Johnson AM, Islam A, Duckworth G, Livermore DM, et al. (2007) Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 335: 982.
48. Levin BR, Rozen DE, (2006) Non-inherited antibiotic resistance. Nat Rev Microbiol 4: 556-562.